MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why INTS Stock slipped -1.18% Today — RQD Quant Desk Flash
$3.34 -1.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.33
Intensity Therapeutics Inc. (INTS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $10.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.33 (-0.40%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INTS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY INTS SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (32% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 47.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (21% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$3.63-7.7% Next Q
55
Q2 (-2Q)Grade C-$3.35-3% Next Q
52
Q3 (-1Q)Grade C-$3.25+2.8% Next Q
50
CurrentGrade D$3.34-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INTS Turnaround Squeeze
While INTS currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.77) and Max Pain ($3.51) forces dealer call-delta covering toward $18.56.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INTS Stock slipped -1.18% Today — RQD Quant Desk Flash
Intensity Therapeutics Inc. (INTS) slipped -1.18% to $3.34, trading at 2% of its 52-week range ($3 – $17.68). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3 – $17.68) with RSI-14 at 47.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.34 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live INTS Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INTS)
- ✓Walkthrough of INTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.89%▼ DESCENDING CHANNEL
2026-10-30O $3.41H $3.45L $3.21C $3.34VOL 16.1K
RES: $5.06SUP: $2.77SMA50: $3.77SMA200: $5.22
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INTS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INTS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INTS)
Health Care Rank #425 of 1016
⚔️ PASG vs INTS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INTS vs. PASG, INAB, ATYR, BCDA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Intensity Therapeutics Inc. (INTS) ranks #425 by composite RQD confidence (47/100, grade D) and #891 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, INTS leads on earnings valuation at N/A trailing P/E, while INTS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INTS at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INTS
ACTIVE
Intensity Therapeutics Inc. | D | 47/100 | — | — | -35.0% | -1.18% | $10.9M | Benchmark Subject |
| PASG Passage Bio Inc. | D | 51/100 | — | — | -35.0% | +5.71% | $11.3M | /pasg-vs-ints → |
| INAB IN8bio Inc. | D- | 38/100 | — | — | -35.0% | -3.91% | $9.7M | /inab-vs-ints → |
| ATYR aTyr Pharma Inc. | D | 44/100 | — | — | -35.0% | +4.56% | $13.5M | /atyr-vs-ints → |
| BCDA BioCardia Inc. | D | 49/100 | — | — | -35.0% | -2.26% | $14.0M | /bcda-vs-ints → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001567264In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intensity Therapeutics Inc. (INTS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.6M, operating cash flow of -$9.2M, and free cash flow of -$9.2M (+39.3% YoY). On the balance sheet, INTS closed FY2025 with $14.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$11.6M | -$9.2M | -$9.2M | $14.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$16.3M | -$15.2M | -$15.2M | $4.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.5M | -$7.2M | -$7.2M | — | — |
3. INTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Intensity Therapeutics Inc. (NASDAQ: INTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.34 (-1.18% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INTS ranks #425 in composite RQD confidence.
How does INTS compare to PASG and INAB in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INTS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PASG (Passage Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M) and INAB (IN8bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $9.7M). Among the 5-stock peer group, INTS leads on earnings multiple (N/A) while INTS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INTS?
Per INTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001567264), Intensity Therapeutics Inc. generated $0 in revenue, -$11.6M in net income, and -$9.2M in free cash flow against $14.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INTS trading relative to its 50-day, 200-day, and 52-week technical levels?
INTS last traded at $3.34 (-1.18% on volume of 7,656 shares), positioning the stock -11.41% below its 50-day simple moving average ($3.77) and -36.02% below its 200-day simple moving average ($5.22). Across its 52-week range of $3.00 to $17.68, INTS sits at the 2.3% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.92 to $3.76).
INTS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INTS stock moving today?
Why INTS Stock slipped -1.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.